Mga Batayang Estadistika
| LEI | 549300066CFEWOA17F12 |
| CIK | 1750149 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inhibikase Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
EX-99.2 Corporate Overview August 2025 Exhibit 99.2 Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “we”) intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 14, 2025 |
Amendment No. 3 to the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 3 TO THE INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN The Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan (as amended, the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”), but subject to approval by the Company’s stockholders in accordance wit |
|
| August 14, 2025 |
EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity August 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financia |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 25, 2025 |
CORRESP VIA EDGAR June 25, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inhibikase Therapeutics, Inc. |
|
| June 20, 2025 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.5 INHIBIKASE THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| June 20, 2025 |
Form of Senior Indenture between Registrant and one or more trustees to be named EX-4.4 Exhibit 4.4 INHIBIKASE THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM June 20, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com |
|
| June 12, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 14, 2025 |
Exhibit 99.1 Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity —Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — May 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to t |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIB |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 14, 2025 |
Exhibit 99.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Inhibikase Therapeutics, Inc. (the “Company”), and David McIntyre (the “Executive”) and is effective on the first business day it becomes fully executed (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditi |
|
| April 14, 2025 |
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer Exhibit 99.3 Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer April 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today announced the appointment of David McIntyre as Chief F |
|
| April 14, 2025 |
Exhibit 99.1 CONSULTING AGREEMENT This “Agreement” is made and entered into as of April 11, 2025 (the “Effective Date”) by and between Garth Lees-Rolfe (“Consultant”) and Inhibikase Therapeutics, Inc. (with its successors and assigns, the “Company”) (each a “Party” and collectively the “Parties”). The Company and Consultant hereby agree as follows: 1. Services. The Company hereby engages Consultan |
|
| March 27, 2025 |
EXHIBIT 10.27 CONSULTING AGREEMENT This “Agreement” is made and entered into as of February 13, 2025 (the “Effective Date”) by and between Dr. Milton Werner (“Consultant”) and Inhibikase Therapeutics, Inc. (with its successors and assigns, the “Company”) (each a “Party” and collectively the “Parties”). The Company and Consultant hereby agree as follows: 1. Services. The Company hereby engages Cons |
|
| March 27, 2025 |
Exhibit 99.1 Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity — New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — March 27, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhib |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 27, 2025 |
CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10) AND REPLACED WITH [***]. |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
Form of Non-Qualified Stock Option Agreement (Non-Plan Inducement Grant) EXHIBIT 10.30 INHIBIKASE THERAPEUTICS, INC. NON-QUALIFIED STOCK OPTION AGREEMENT (INDUCEMENT GRANT) Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”) hereby grants to the individual listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the |
|
| March 27, 2025 |
Amended & Restated Insider Trading Policy EXHIBIT 19.1 INHIBIKASE THERAPEUTICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY I. Purpose Inhibikase Therapeutics, Inc. (the “Company”) has adopted this Insider Trading Policy (as may be amended, restated and/or otherwise modified from time to time in accordance with its terms, this “Policy”) to satisfy the Company’s obligation to prevent the misuse of material nonpublic information, insid |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, |
|
| March 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Inhibikase Therapeutics, Inc. |
|
| March 27, 2025 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF INHIBIKASE THERAPEUTICS, INC. Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. Name of Subsidiary Jurisdiction of Incorporation or Organization Percent of Outstanding Voting Securities Owned IKT Securities Co |
|
| March 27, 2025 |
EXHIBIT 10.28 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Inhibikase Therapeutics, Inc. (the “Company”), and Mark Iwicki (the “Executive”) and is effective on the first business day after it becomes fully executed (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and con |
|
| March 27, 2025 |
EXHIBIT 10.29 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Inhibikase Therapeutics, Inc. (the “Company”), and Chris Cabell (the “Executive”) and is effective on the first business day it becomes fully executed (the “Effective Date”). WHEREAS, this Agreement is being entered into in anticipation of the acquisition of CorHepta Pharmaceuticals, Inc. by the Company (the |
|
| February 24, 2025 |
EX-99.1 Exhibit 99.1 Inhibikase Announces Expansion of Senior Leadership Team —- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development —- —- John Adams, PhD Appointed Chief Scientific Officer —- —- Vince Aurentz to join Inhibikase Board of Directors —- February 24, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appoint |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 18, 2025 |
Exhibit 99.1 Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth —Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases — Amit Munshi Appointed Chair of the Board of Directors BOSTON, MA and ATLANTA, GA February 18, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company |
|
| February 14, 2025 |
EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0. |
|
| February 4, 2025 |
Amendment No. 1 to Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan Exhibit 99.2 AMENDMENT TO THE INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN. The Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan (the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”), but subject to approval by the Company’s stockholders in accordance with Section 11 of t |
|
| February 4, 2025 |
Amendment No. 2 to Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan Exhibit 99.3 AMENDMENT TO THE INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN. The Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan (the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”), but subject to approval by the Company’s stockholders in accordance with Section 11 of t |
|
| February 4, 2025 |
As filed with the Securities and Exchange Commission on February 4, 2025 As filed with the Securities and Exchange Commission on February 4, 2025 Registration No. |
|
| February 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inhibikase Therapeutics, Inc. |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 14, 2025 |
CORRESP Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 January 14, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Joshua Gorsky Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284222 Ladi |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025. Table of Contents As filed with the Securities and Exchange Commission on January 10, 2025. |
|
| January 10, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inhibikase Therapeutics, Inc. |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 6, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBIKASE THERAPEUTICS, INC. Inhibikase Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: First: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporatio |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2024 Inhibikase Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39676 26-3407249 (State or other jurisdiction of incorporation) (Com |
|
| December 5, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-283307 PROSPECTUS Inhibikase Therapeutics, Inc. Up to 58,310,000 Shares of Common Stock Up to 21,985,000 Shares of Common Stock Underlying Pre-Funded Warrants This prospectus relates to the sale or other disposition from time to time of (i) up to 58,310,000 shares of our common stock, $0.001 par value per share, and (ii) up to |
|
| December 3, 2024 |
As filed with the Securities and Exchange Commission on December 2, 2024. S-3/A Table of Contents As filed with the Securities and Exchange Commission on December 2, 2024. |
|
| December 3, 2024 |
Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 December 3, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alan Campbell Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed November 18, 2024 File No. 333-283307 Ladies and |
|
| November 18, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024. S-3 Table of Contents As filed with the Securities and Exchange Commission on November 18, 2024. |
|
| November 18, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inhibikase Therapeutics, Inc. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 14, 2024 |
IKT / Inhibikase Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⃞ Defin |
|
| October 28, 2024 |
EX-99.1 2 d858428dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of |
|
| October 28, 2024 |
IKT / Inhibikase Therapeutics, Inc. / SP IKT Holdings LLC - SC 13G Passive Investment SC 13G 1 d858428dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Amendment No )* Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W205 (CUSIP Number) October 21, 2024 (Date of Event which Requires Filing of this Statement) Check |
|
| October 28, 2024 |
SC 13G 1 ea0218544-13gsoleus3inhibi.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibikase Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W205 (CUSIP Number) October 21, 2024 (Date of Event Which Requires Filing of t |
|
| October 25, 2024 |
SC 13G 1 d840359dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibikase Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0 |
|
| October 22, 2024 |
IKT / Inhibikase Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d829059dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibikase Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W205 (CUSIP Number) October 21, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| October 22, 2024 |
EX-99.1 2 d829059dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 22, 20 |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 22, 2024 |
Exhibit 99.1 Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension — IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 – BOSTON and ATL |
|
| October 17, 2024 |
IKT / Inhibikase Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13G Passive Investment SC 13G 1 tm2426286d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibikase Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W205 (CUSIP Number) Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite |
|
| October 17, 2024 |
IKT / Inhibikase Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 11, 2024 |
SC 14F1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER INHIBIKASE THERAPEUTICS, INC. (Name of Registrant) Delaware 001-39676 26-3407249 (State of Incorporation) (Commission File No.) (IRS Employer Identification No.) 3350 Riverwood Parkway SE, Sui |
|
| October 10, 2024 |
SC 13G 1 p24-2958sc13g.htm INHIBIKASE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibikase Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W205 (CUSIP Number) October 9, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 10, 2024 |
Exhibit 10.3 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is entered into as of October [●], 2024, by and between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and the investor whose name appears on the signature page hereto (the “Stockholder”). WHEREAS, the Company and certain investors (the “Investors”), including the Stockholder, entered into a Securities |
|
| October 10, 2024 |
Exhibit 10.4 VIA EMAIL ONLY [•], 2024 [name] Re: Director Offer Letter [•], This Director Offer Letter constitutes an agreement (“Agreement”) between you and Inhibikase Therapeutics, Inc. (“Company”) and contains all of the terms and conditions relating to your service to the Company as a Class [•] member of our Board of Directors (“Board”). 1. Term. This Agreement will become effective on October |
|
| October 10, 2024 |
Securities Purchase Agreement, dated as of October 9, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 9, 2024, by and among Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliv |
|
| October 10, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-2958exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| October 10, 2024 |
Form of Series B-1 Warrant (October 2024) Exhibit 4.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT, OR PRE-FUNDED WARRANTS IN LIEU THEREOF (THE “SECURITIES”), HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSI |
|
| October 10, 2024 |
Settlement Agreement, dated as of September 30, 2024 Exhibit 10.5 EXECUTION COPY SETTLEMENT AGREEMENT This Settlement Agreement is made on this 30th day of September 2024 and entered into by and between Inhibikase Therapeutics, Inc. (“Inhibikase”), and Pivot Holding LLC (“Pivot”), as successor in interest to Sphaera Pharma Pte. Ltd. (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd. (“Sphaera India,” and together with Sphaera Singapore, “Sphaera”) ( |
|
| October 10, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October [●], 2024, is entered into by and among Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized |
|
| October 10, 2024 |
Form of Series A-1 Warrant (October 2024) Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT, OR PRE-FUNDED WARRANTS IN LIEU THEREOF (THE “SECURITIES”), HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSI |
|
| October 10, 2024 |
Form of Pre-Funded Warrant (October 2024) Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN |
|
| October 10, 2024 |
Exhibit 99.1 Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension — Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital — BOSTON and ATLANTA, October 9, 2024 — Inhibikase Therapeutics, Inc. (Nas |
|
| October 9, 2024 |
Exhibit 99.1 PAH | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Pulmonary Arterial Hypertension Inhibikase.com : IKT DISCLAIMER This presentation contains information that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Inhibikase Therapeutics |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 27, 2024 |
4,761,904 shares of Common Stock Inhibikase Therapeutics, Inc. Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280317 PROSPECTUS 4,761,904 shares of Common Stock Inhibikase Therapeutics, Inc. This prospectus relates to the resale from time to time, by the selling stockholder (the “Selling Stockholder”) identified in this prospectus under the caption “Selling Stockholder” of up to 4,761,904 shares of common stock, par value $0.001 per s |
|
| June 24, 2024 |
Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 June 24, 2024 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 June 24, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-1 Filed June 18, 2024 File No. 333-280317 Ladies and Gentlem |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 18, 2024 |
Power of Attorney (included on signature page). S-1 Table of Contents As filed with the Securities and Exchange Commission on June 18, 2024. |
|
| June 18, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) Inhibikase Therapeutics, Inc. |
|
| June 18, 2024 |
Support Agreement, dated as of May 20, 2024, by and between the Company and Milton H. Werner, Ph.D. Exhibit 10.20 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is entered into as of May 20, 2024, by and between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”) and the stockholder whose name appears on the signature page hereto (the “Stockholder”). WHEREAS, the Company and a certain investor (the “Investor”) entered into a Securities Purchase Agreement, of even d |
|
| June 18, 2024 |
Form of Lock-Up Agreement (May 2024). Exhibit 10.19 Form of Lock-Up Agreement May 22, 2024 Maxim Group LLC 300 Park Ave, 16th Floor New York, NY 10022 Re: Placement of Inhibikase Therapeutics, Inc. Ladies and Gentlemen: The undersigned, a holder of securities of Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), understands that you are the placement agent (the “Placement Agent”) named in the letter agreement dated |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⃞ Defin |
|
| May 22, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-262551 PROSPECTUS SUPPLEMENT (To prospectus dated February 11, 2022) INHIBIKASE THERAPEUTICS, INC. 714,527 Shares of Common Stock 957,925 Pre-Funded Warrants to Purchase up to 957,925 Shares of Common Stock 957,925 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering (i) 714,527 shares of our common stock, |
|
| May 20, 2024 |
Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE |
|
| May 20, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| May 20, 2024 |
Securities Purchase Agreement, dated as of May 20, 2024 Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 20, 2024, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th |
|
| May 20, 2024 |
Exhibit 4.5 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE |
|
| May 20, 2024 |
Exhibit 99.1 Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify t |
|
| May 20, 2024 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 20, 2024 |
Exhibit 4.3 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE |
|
| May 20, 2024 |
Exhibit 4.6 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of May 22, 2024, by and between Inhibikase Therapeutics Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund, Ltd. (the “Holder”). WHEREAS, the Holder is the holder of Common Stock Purchase Warrants issued on January 27, 2023 (the |
|
| May 20, 2024 |
Exhibit 4.4 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE |
|
| May 20, 2024 |
INHIBIKASE THERAPEUTICS, INC. Up to $50,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262551 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated February 11, 2022 and the Prospectus Supplement, dated February 1, 2024) INHIBIKASE THERAPEUTICS, INC. Up to $50,000 Common Stock We have entered into an At the Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, relating to shares of our |
|
| May 20, 2024 |
Placement Agency Agreement, dated as of May 20, 2024 Exhibit 10.2 EXECUTION VERSION PLACEMENT AGENCY AGREEMENT May 20, 2024 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 Attn: Milton H. Werner, Ph.D. President and Chief Executive Officer This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC, as placement agent (“Maxim”) and Inhibikase Therapeutics, Inc., a Delaware corporation ( |
|
| May 20, 2024 |
Inducement Letter, dated as of May 20, 2024 Exhibit 10.3 EXECUTION VERSION INHIBIKASE THERAPEUTICS, INC. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 May 20, 2024 To the Holder of January 2023 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: INHIBIKASE THERAPEUTICS, INC. (the “Company”) is pleased to offer to you the opportunity to exercise the warrants to p |
|
| May 15, 2024 |
Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 May 15, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549-3720 Attention: Jessica L. Dickerson Re: Inhibikase Therapeutics, Inc. Request to Withdraw Registration Statement on Form S-1 File No. 333-278844 Ladies and |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| May 9, 2024 |
Form of Securities Purchase Agreement. EX-10.19 Exhibit 10.19 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2024, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| May 9, 2024 |
EX-4.11 Exhibit 4.11 COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: May [•], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”, which term shall include any institution that has an account with the Depositary (or a designee appointed by such institution)) is entitled, upon |
|
| May 9, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Inhibikase Therapeutics, Inc. |
|
| May 9, 2024 |
Form of Warrant Agency Agreement. EX-4.14 Exhibit 4.14 INHIBIKASE THERAPEUTICS, INC. and EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of [ ] , 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of [ ] , 2024 (“Agreement”), between Inhibikase Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC, a limite |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 8, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 8, 2024 Registration No. |
|
| May 9, 2024 |
Form of Placement Agency Agreement. EX-1.1 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [•], 2024 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 Attn: Milton H. Werner, Ph.D. President and Chief Executive Officer This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC, as placement agent (“Maxim”) and Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 30, 2024 |
Exhibit 99.1 2Q24 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease, Cancer and Cardiopulmonary Disease Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, |
|
| April 29, 2024 |
As filed with the Securities and Exchange Commission on April 29, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 29, 2024 Registration No. |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2024 |
EX-4.11 Exhibit 4.11 COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: April [•], 2024 Issue Date: April [•], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| April 25, 2024 |
EX-4.12 Exhibit 4.12 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| April 25, 2024 |
Form of Securities Purchase Agreement. EX-10.19 Exhibit 10.19 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [•], 2024, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| April 25, 2024 |
Form of Placement Agent Warrant EX-4.13 Exhibit 4.13 PLACEMENT AGENT PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: October [•], 2024 Issue Date: April [•], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo |
|
| April 25, 2024 |
As filed with the Securities and Exchange Commission on April 25, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 25, 2024 Registration No. |
|
| April 25, 2024 |
Form of Placement Agency Agreement. EX-1.1 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT April [●], 2024 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 Attn: Milton H. Werner, Ph.D. President and Chief Executive Officer This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC, as placement agent (“Maxim”) and Inhibikase Therapeutics, Inc., a Delaware corporation (the “Compa |
|
| April 19, 2024 |
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs Exhibit 99.1 Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs BOSTON and ATLANTA, April 18, 2024 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other di |
|
| April 19, 2024 |
As filed with the Securities and Exchange Commission on April 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 19, 2024 Registration No. |
|
| April 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Inhibikase Therapeutics, Inc. |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 19, 2024 |
Exhibit 10.18 INHIBIKASE THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of April 1, 2024 (the “Effective Date”), by and between INHIBIKASE THERAPEUTICS, INC. (the “Company”), and Garth Lees-Rolfe (the “Employee”). WHEREAS, the parties hereto wish to enter into an employment agreement to employ the Employee as Chief Financi |
|
| April 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 2, 2024 |
INHIBIKASE THERAPEUTICS, INC. EMPLOYMENT AGREEMENT Exhibit 99.1 INHIBIKASE THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of April 1, 2024 (the “Effective Date”), by and between INHIBIKASE THERAPEUTICS, INC. (the “Company”), and Garth Lees-Rolfe (the “Employee”). WHEREAS, the parties hereto wish to enter into an employment agreement to employ the Employee as Chief Financia |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, |
|
| March 27, 2024 |
EXHIBIT 14.1 INHIBIKASE THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS Effective December 22, 2020, as amended on November 11, 2021 • Introduction This Code of Business Conduct and Ethics (“Code”) has been adopted by the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (together with its subsidiaries, the “Company”) and summarizes the standards that must guide the actions |
|
| March 27, 2024 |
EXHIBIT 97.1 Inhibikase Therapeutics, Inc. (the “Company”) Compensation Clawback Policy Effective Date: October 2, 2023 1. Purpose. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, and Nasdaq Listing Rule 5608, which require the recovery of certain forms of execut |
|
| March 27, 2024 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF INHIBIKASE THERAPEUTICS, INC. Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. Name of Subsidiary Jurisdiction of Incorporation or Organization Percent of Outstanding Voting Securities Owned IKT Securities Co |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 7, 2024 |
Exhibit 99.1 Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers - The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease - - BOSTON and ATLANTA, February 7, 2024 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Com |
|
| February 1, 2024 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT February 1, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Inhibikase Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in |
|
| February 1, 2024 |
INHIBIKASE THERAPEUTICS, INC. Up to $5,659,255 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262551 PROSPECTUS SUPPLEMENT (To prospectus dated February 11, 2022) INHIBIKASE THERAPEUTICS, INC. Up to $5,659,255 Common Stock We have entered into an At the Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, relating to shares of our common stock offered by this prospect |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 16, 2024 |
EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli - Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer — BOSTON and ATLANTA, January 16, 2024 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical co |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIK |
|
| September 20, 2023 |
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity Exhibit 99.1 Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity BOSTON and ATLANTA, September 20, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other |
|
| September 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (C |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| July 17, 2023 |
By electronic delivery to: [email protected]; [email protected] EX-99.1 Exhibit 99.1 By electronic delivery to: [email protected]; [email protected] July 17, 2023 Dr. Milton H. Werner Chief Executive Officer Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 Re: Inhibikase Therapeutics, Inc. (the “Company”) Nasdaq Symbol: IKT Dear Dr. Werner: On July 25, 2022, Staff notified the Company that its common sto |
|
| July 17, 2023 |
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements EX-99.2 Exhibit 99.2 Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements BOSTON and ATLANTA, July 17, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the A |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 29, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBIKASE THERAPEUTICS, INC. Inhibikase Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incor |
|
| June 29, 2023 |
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split BOSTON and ATLANTA, June 29, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyros |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 21, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 4, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-269521 PROSPECTUS Up to 11,627,908 shares of Common Stock underlying the Common Warrants Up to 4,883,721 shares of Common Stock underlying the Pre-Funded Warrants Up to 406,977 shares of Common Stock underlying the Placement Agent Warrants Inhibikase Therapeutics, Inc. This prospectus relates to the resale from time to time, b |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, |
|
| March 31, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES OF INHIBIKASE THERAPEUTICS, INC. Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. Name of Subsidiary Jurisdiction of Incorporation or Organization Percent of Outstanding Voting Securities Owned IKT Securities Co |
|
| March 31, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on March 31, 2023. |
|
| March 22, 2023 |
EX-99.1 Exhibit 99.1 March 22, 2023| Inhibikase Neurodegeneration R&D Day Transforming fundamental and clinical research in neurodegenerative disease Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Shares (Title of Class of Securities) 45719W106 (CUSIP Number) FiveT Investment Management Ltd c/o Waystone Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way Camana Bay, Grand Cayman, Cayman Islands KY1-1108 +1 34 |
|
| February 16, 2023 |
IKT / Inhibikase Therapeutics Inc / Werner Milton H. - SC 13G/A Passive Investment SC 13G/A 1 d442043dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* INHIBIKASE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| February 8, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-269521 PROSPECTUS Up to 11,627,908 shares of Common Stock underlying the Common Warrants Up to 4,883,721 shares of Common Stock underlying the Pre-Funded Warrants Up to 406,977 shares of Common Stock underlying the Placement Agent Warrants Inhibikase Therapeutics, Inc. This prospectus relates to the resale from time to t |
|
| February 3, 2023 |
Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 February 3, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-1 Filed February 2, 2023 File No. 333-269521 Ladies |
|
| February 2, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) INHIBIKASE THERAPEUTICS, INC. |
|
| February 2, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on February 1, 2023. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Shares (Title of Class of Securities) 45719W106 (CUSIP Number) FiveT Investment Management Ltd c/o Waystone Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way Camana Bay, Grand Cayman, Cayman Islands KY1-1108 +1 34 |
|
| January 27, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262551 PROSPECTUS SUPPLEMENT (To prospectus dated February 11, 2022) INHIBIKASE THERAPEUTICS, INC. 2,800,789 Shares of Common Stock Pre-funded Warrants to Purchase up to 3,943,398 Shares of Common Stock We are offering (i) 2,800,789 shares of our common stock, $0.001 par value per share, and (ii) Pre-funded Warrants (“Pr |
|
| January 26, 2023 |
Registration Rights Agreement, dated as of January 25, 2023 (PIPE) EX-10.3 Exhibit 10.3 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 25, 2023, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant |
|
| January 26, 2023 |
Securities Purchase Agreement, dated as of January 25, 2023 (PIPE) EX-10.2 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 25, 2023, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the ter |
|
| January 26, 2023 |
EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of |
|
| January 26, 2023 |
Exhibit 4.4 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| January 26, 2023 |
Form of PIPE Pre-Funded Warrant EX-4.3 Exhibit 4.3 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39676 (Commission Fil |
|
| January 26, 2023 |
Securities Purchase Agreement, dated as of January 25, 2023 (Registered Direct) EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 25, 2023, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the term |
|
| January 26, 2023 |
EX-4.1 Exhibit 4.1 EXHIBIT A-1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| January 26, 2023 |
Form of Placement Agent Warrant EX-4.5 Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| January 26, 2023 |
Form of Private Common Warrant EX-4.2 Exhibit 4.2 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| January 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 25, 2023 |
Exhibit 99.2 Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson’s Disease and Related Disorders - Animal model studies highlight potential of the c-Abl inhibitor IkT-148009 to modify the course of Parkinson’s Disease and Suppress Protein Pathology - BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. (Nasdaq: IK |
|
| January 25, 2023 |
Exhibit 99.1 Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson’s Disease - Phase 2a ‘201’ clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured in healthy subjects at the 200 mg dose prior to implementation in the 201 trial- BOSTON and ATLANTA, January 25, 2023 — Inhibikase |
|
| January 24, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Co |
|
| November 17, 2022 |
Exhibit 99.1 Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity Company to host conference call and webcast on November 15, 2022 at 8:00am ET BOSTON and ATLANTA, November 14, 2022 ? Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (?Inhibikase? or ?Company?), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| November 7, 2022 |
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs BOSTON and ATLANTA, November 7 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (C |
|
| September 16, 2022 |
Conference Presentation of Inhibikase Therapeutics, Inc. Exhibit 99.1 IkT-148009 As A Potential Disease-Modifying Therapy in Parkinson?s Disease Poster 789 Werner MH,1,7 Karuppagounder SS,2,3 Rush R,1 Kelly T,1 Dawson TM,2-3,5,7 Dawson VL2-4,6,7 1Inhibikase Therapeutics, Inc., Atlanta, GA, 30339, USA; 2Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 3Departm |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 1, 2022 |
Form of Director Offer Letter. Exhibit 10.1 VIA EMAIL ONLY [email protected] Ms. Gisele Dion 40 Tamarack Terrace Stoneham MA 02180 Re: Director Offer Letter Dear Gisele, This Director Offer Letter constitutes an agreement (?Agreement?) between you and Inhibikase Therapeutics, Inc. (?Company?) and contains all of the terms and conditions relating to your service to the Company as a Class II member of our Board of Directors (?Boa |
|
| September 1, 2022 |
Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors Exhibit 99.1 Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors BOSTON and ATLANTA, September 1, 2022 ? Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson?s disease and related disorders as well as other diseases arising from protein kinases, today announced the appointment of M |
|
| August 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 15, 2022 |
Exhibit 99.1 3Q 2022 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease & Cancer Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale w |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| July 29, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 29, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39676 (Commission File N |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| May 17, 2022 |
Piper Sandler The date of this prospectus supplement is May 16, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262551 PROSPECTUS SUPPLEMENT (To prospectus dated February 11, 2022) INHIBIKASE THERAPEUTICS, INC. Up to $9,801,287 Common Stock We have entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, relating to shares of our common stock offered by this prospec |
|
| May 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 17, 2022 |
Exhibit 10.1 Execution Version INHIBIKASE THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENT May 16, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Inhibikase Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell from time to time through Pipe |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| May 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy St |
|
| May 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 21, 2022 |
Clinical Development of Disease- Modifying Therapeutics for Parkinson?s and Related Disorders 2Q 2022 BUSINESS PRESENTATION IKT Exhibit 99. |
|
| March 31, 2022 |
Subsidiaries of the Registrant EXHIBIT 21 SUBSIDIARIES OF INHIBIKASE THERAPEUTICS, INC. Registrant?s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. Name of Subsidiary Jurisdiction of Incorporation or Organization Percent of Outstanding Voting Securities Owned IKT Securities Corp |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THE |
|
| March 24, 2022 |
EX-99.1 2 d320841dex991.htm EX-99.1 Exhibit 99.1 IKT Parkinson’s Disease Modification Through Abl-kinase Inhibition AD-PD 2022, March 18 2022 Disclosures Dr. Milton Werner is the Founder, Chief Executive and largest shareholder of Inhibikase Therapeutics, Inc. 2 2 Disclaimer This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there |
|
| March 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 8, 2022 |
Exhibit 10.1 Amendment 1 Employment Agreement for Milton H. Werner, PhD Chief Executive Officer and President Pursuant to the Compensation Committee recommendations of February 24, 2022 to the Board of Directors of Inhibikase Therapeutics, Inc. (the ?Company?), the following modification is made to the Employment Agreement of Dr. Milton Werner dated December 28, 2020: 1. Article 4(b) is stricken i |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 8, 2022 |
Exhibit 10.2 Amendment 1 Employment Agreement for Joseph Frattaroli Chief Financial Officer Pursuant to the Compensation Committee recommendations of February 24, 2022 to the Board of Directors of Inhibikase Therapeutics, Inc., the following modification is made to the Employment Agreement of Joseph Frattaroli dated October 24, 2018: 1. Article 3(a) is stricken in its entirety and replaced with th |
|
| March 8, 2022 |
Form of Stock Option Grant Notice and Award Agreement. Exhibit 10.3 INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND AWARD AGREEMENT Inhibikase Therapeutics, Inc., a Delaware corporation (the ?Company?), pursuant to its 2020 Equity Incentive Plan (the ?Plan?), hereby grants to the individual listed below (?Participant?) an option to purchase the number of Shares set forth below (the ?Option?). The Option described |
|
| February 11, 2022 |
IKT / Inhibikase Therapeutics Inc / Werner Milton H. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* INHIBIKASE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 9, 2022 |
Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 February 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Jordan Nimitz Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 SEC File No. 333-262551 Filed February 4, 2022 Ladies and Gent |
|
| February 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inhibikase Therapeutics, Inc. |
|
| February 7, 2022 |
Exhibit 4.2 INHIBIKASE THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 3 Section 1.4. Rules of Construction 3 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series 4 Section 2.2. Est |
|
| February 7, 2022 |
As filed with the Securities and Exchange Commission on February 4, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 4, 2022 Registration No. |
|
| January 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2022 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| January 20, 2022 |
Exhibit 99.1 Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson?s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT 2 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unl |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Shares (Title of Class of Securities) 45719W106 (CUSIP Number) FiveT Investment Management Ltd c/o Waystone Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way Camana Bay, Grand Cayman, Cayman Islands KY1-1108 +1 34 |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Shares (Title of Class of Securities) 45719W106 (CUSIP Number) FiveT Investment Management Ltd c/o Waystone Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way Camana Bay, Grand Cayman, Cayman Islands KY1-1108 +1 34 |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| October 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| October 19, 2021 |
Exhibit 99.1 Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson?s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT 2 2 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be u |
|
| September 15, 2021 |
As filed with the United States Securities and Exchange Commission on September 15, 2021 As filed with the United States Securities and Exchange Commission on September 15, 2021 Registration No. |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2021 INHIBIKASE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39676 26-3407249 (State or other jurisdiction (Commission File Numb |
|
| August 17, 2021 |
Exhibit 99.1 IKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson?s and Related Disorders 3Q 2021 BUSINESSPRESENTATIONExhibit 99.1 IKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson?s and Related Disorders 3Q 2021 BUSINESSPRESENTATION Disclaimer This presentation shall not constitute an offer to sell or a solicitation of |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. |
|
| June 29, 2021 |
Submission of Matters to a Vote of Security Holders 8-K 1 d139845d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001 |
|
| June 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Shares (Title of Class of Securities) 45719W106 (CUSIP Number) FiveT Investment Management Ltd c/o Waystone Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way Camana Bay, Grand Cayman, Cayman Islands KY1-1108 +1 34 |
